No. 054 · Combos · Peptide Blend
Tesamorelin + Ipamorelin
- Not approved as a combo
- WADA ✗ S2
Combos are blends of separate compounds, so there is no single sequence. This ring motif is decorative — open a component for its fingerprint.
Quick answers
- What is Tesamorelin + Ipamorelin?
- A potent GH blend combining the FDA-approved GHRH analog Tesamorelin with Ipamorelin for targeted visceral fat reduction and comprehensive growth hormone optimization. Tesamorelin (stabilized GHRH analogue) plus ipamorelin.
- What is in Tesamorelin + Ipamorelin?
- Tesamorelin + Ipamorelin typically combines Tesamorelin and Ipamorelin. Commercial products vary.
- How strong is the evidence for Tesamorelin + Ipamorelin?
- It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. Tesamorelin alone is FDA-approved (Egrifta) on the strength of phase 3 RCTs; ipamorelin has small human pharmacology studies.
- Is Tesamorelin + Ipamorelin FDA-approved?
- No. Tesamorelin + Ipamorelin is not an approved product; no regulator has reviewed the combination. Only tesamorelin on its own is approved (Egrifta); the combination is not.
- Is Tesamorelin + Ipamorelin banned in sport?
- Yes. Tesamorelin + Ipamorelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).
- How does Tesamorelin + Ipamorelin work?
- This blend pairs the FDA-approved GHRH analog tesamorelin (which activates GHRH receptor/cAMP signaling with enhanced enzymatic stability) with ipamorelin (selective ghrelin receptor agonist). Tesamorelin specifically targets visceral fat reduction through GH-mediated lipolysis, while ipamorelin amplifies the GH pulse without cortisol or prolactin elevation.
- What is known about the safety of Tesamorelin + Ipamorelin?
- Tesamorelin is FDA-approved (Egrifta) with Phase III safety data. Ipamorelin has Phase II human data.
Last reviewed · editorial policy · markdown
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
Not ranked: combinations have no published studies of their own. See the components below.
A PubMed search found no published studies of this combination; only reviews mention it. Tesamorelin alone is FDA-approved (Egrifta) on the strength of phase 3 RCTs; ipamorelin has small human pharmacology studies.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Routes studied
- Subcutaneous, Intramuscular Routes used in published research
- FDA
- Not approved as a combination Only tesamorelin on its own is approved (Egrifta); the combination is not.
- WADA
- Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
Overview
A potent GH blend combining the FDA-approved GHRH analog Tesamorelin with Ipamorelin for targeted visceral fat reduction and comprehensive growth hormone optimization.
Research status No published studies of the combination; tesamorelin alone is FDA-approved (Egrifta) based on phase 3 RCTs; ipamorelin has small human pharmacokinetic studies
Mechanism
This blend pairs the FDA-approved GHRH analog tesamorelin (which activates GHRH receptor/cAMP signaling with enhanced enzymatic stability) with ipamorelin (selective ghrelin receptor agonist). Tesamorelin specifically targets visceral fat reduction through GH-mediated lipolysis, while ipamorelin amplifies the GH pulse without cortisol or prolactin elevation.
Effects reported in research
These outcomes are attributed to the individual components. The combination itself has not been studied.
- Significant visceral fat reduction
- Robust GH and IGF-1 elevation
- Improved lipid profiles
- Enhanced body composition and recovery
Safety & unknowns
Tesamorelin is FDA-approved (Egrifta) with Phase III safety data. Ipamorelin has Phase II human data. Combined side effects may include injection site reactions, arthralgia, water retention, headache. Tesamorelin is contraindicated in active malignancy and pregnancy. Monitor IGF-1 levels. Not FDA-approved as a combination.
Unknowns. The combination itself has not been studied; interactions between its components are unknown.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [2]
- Clinical trial 2007
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Phase 3 RCT of the tesamorelin component in HIV patients with abdominal fat accumulation: visceral fat fell 15.2% with tesamorelin versus a 5.0% rise with placebo over 26 weeks.
- Preclinical 1998
Ipamorelin, the first selective growth hormone secretagogue
Rat and swine study on the ipamorelin component showing selective GH release without increases in ACTH or cortisol.
Components
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- Drugs@FDA — NDA 022505 Egrifta (tesamorelin) accessdata.fda.gov
- Falutz et al. 2007 — tesamorelin phase 3 RCT (NEJM) pubmed.ncbi.nlm.nih.gov
- Gobburu et al. 1999 — ipamorelin PK/PD in human volunteers pubmed.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List — S2.2.4 names tesamorelin and ipamorelin wada-ama.org
Cite this entry
peptidemeta. (2026). Tesamorelin + Ipamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/tesamorelin-ipamorelin/
@misc{peptidemeta-tesamorelin-ipamorelin,
title = {Tesamorelin + Ipamorelin},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/tesamorelin-ipamorelin/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.